• Mashup Score: 5
    Moving towards disease modification in polycythemia vera - 1 year(s) ago

    Polycythemia vera (PV) belongs to the BCR-ABL1-negative myeloproliferative neoplasms and is characterized by activating mutations in JAK2 and clinically present

    Source: ashpublications.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of doctorpemm
      doctorpemm

      🙌 Moving towards #DiseaseModification in PV | #MPNSM || Dr Bewersdorf Dr @joanhowMD Dr @MDmasarova Dr @bose_prithviraj @doctorpemm Dr John Mascarhenas Dr @RaajitRampal || @BloodJournal https://t.co/wIvDWevSph https://t.co/6D5ZSu1bHA

  • Mashup Score: 0
    Systemic mastocytosis: current treatments and emerging targeted agents - 1 year(s) ago

    Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the treatment of patients with advanced, indolent and smoldering systemic mastocytosis (SM), covering anti-mediator and cytotoxic treatments, before highlighting the development of targeted agents. Dr Bose describes the high potency and selectivity of avapritinib and bezuclastinib against mutated KIT kinase, and comments on promising efficacy and safety results from ongoing trials. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #SOHO23 | @bose_prithviraj of @MDAndersonNews shares some insights into current & emerging therapies for systemic mastocytosis, as well as promising results from ongoing trials: 👉 https://t.co/9TMzeVTiqk 👈 @SocietyofHemOnc #HemOnc #RareDiseases

  • Mashup Score: 0
    Phase I/II Study Evaluates Zilurgisertib with or Without Ruxolitinib in Myelofibrosis - 1 year(s) ago

    Home > Meeting News > Phase I/II Study Evaluates Zilurgisertib with or Without Ruxolitinib in Myelofibrosis Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, discusses results of an ongoing open-label, multicenter, phase I/II study of zilurgisertib alone or with ruxolitinib in myelofibrosis. Dr. Bose and colleagues presented the research during the 2023 American Society of Clinical Oncology Annual Meeting. The dose-escalation and dose-expansion study evaluated the safety and

    Source: bloodcancerstoday.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of Blood_Cancers
      Blood_Cancers

      Catching up on the latest data in myelofibrosis? Don't miss this video featuring @bose_prithviraj of @MDAndersonNews discussing an ongoing phase I/II study of zilurgisertib alone or with ruxolitinib in myelofibrosis. 📺https://t.co/44b9ltqqS3 https://t.co/TFQmHFZIjU

  • Mashup Score: 0
    Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm - 1 year(s) ago

    Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      .@bose_prithviraj discusses non-myelosuppressive JAK inhibitors in myelofibrosis, the future of combination therapy in this space, and the importance of enrolling patients in clinical trials specific to their disease subset. @MDAndersonNews #mpnsm https://t.co/GKasOHCm2x

  • Mashup Score: 0
    Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm - 1 year(s) ago

    Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      JAK inhibitor combinations may bolster the efficacy of ruxolitinib monotherapy in patients with myelofibrosis, although more phase 3 research is needed to define the roles of these combinations for certain subsets. @bose_prithviraj @MDAndersonNews #mpnsm https://t.co/EKKbPmoi6O https://t.co/qBWjeZ7Jfp

  • Mashup Score: 1
    Zilurgisertib With or Without Ruxolitinib Shows Early Tolerability, Activity in Anemic Myelofibrosis - 1 year(s) ago

    Administration of the selective ALK-2 inhibitor zilurgisertib alone or in combination with ruxolitinib was safe, well tolerated, and showed preliminary signals of clinical activity in patients with primary or secondary myelofibrosis and disease-related anemia.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Administration of zilurgisertib alone or w. ruxolitinib was safe, well tolerated, & showed preliminary signals of clinical activity in pts w/ primary or secondary myelofibrosis & disease-related anemia. @bose_prithviraj @MDAndersonNews #ASCO23 #oncology https://t.co/rgenasVpoW https://t.co/BobBDd25do

  • Mashup Score: 0
    VJHemOnc – The video journal of hematological oncology - 1 year(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      At #ASCO23 we spoke with @bose_prithviraj of @MDAndersonNews who shared results on the use of zilurgisertib as monotherapy or with ruxolitinib in patients with MF-related anemia More to come on https://t.co/O9p0vDBrzw @ASCO #ASCO23 #HemOnc #Myelofibrosis #Anemia https://t.co/JE5y16kQu4

  • Mashup Score: 0
    VJHemOnc – The video journal of hematological oncology - 1 year(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Day 3 of #ASCO23 and we just spoke to @bose_prithviraj of @MDAndersonNews on zilurgisertib monotherapy or with ruxolitinib in patients with MF-related anemia Don't forget to keep up to date with @ASCO at https://t.co/O9p0vDBrzw #HemOnc #Myelofibrosis #Anemia https://t.co/tWDkVbdTyM

Load More